ClinicalTrials.gg
CompletedNCT04839809Updated Dec 10, 2021

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

A Phase 1 interventional study of CC-92480 and Placebo in Healthy Volunteers, sponsored by Celgene. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-10.

Sponsored by Celgene (part of Bristol-Myers Squibb) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Oct 2021, 5 years 1 month ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

This is a Phase 1 study that will be conducted in 2 parts. Participants may participate in 1 part only.

  • Part 1 will be a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety, tolerability, and PK of CC-92480-02 (Formulation A) administered orally under fasted conditions in healthy adult participants.
  • Part 2 will be a randomized, open-label, 2 × 4 crossover study (Periods 1, 2, 3, and 4) to evaluate the relative bioavailability (RBA) of Formulation A versus Formulation B under fasted conditions and explore safety, tolerability, and PK effects of food on Formulation A and Formulation B in healthy adult participants.
02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • CC-92480
  • Pharmacokinetics
03

In context

Lead sponsor

Celgene is the lead sponsor of 428 studies on the registry; 12 are open to participants now.

Of its 104 completed or terminated interventional studies of FDA-regulated products, 30 (29%) have results posted.

First submitted after Celgene became part of Bristol-Myers Squibb.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants must satisfy the following criteria to be enrolled in the study:

  1. Must understand and voluntarily sign a written form (ICF) prior to any study-related assessments/procedures being conducted.
  2. Healthy adult female of nonchildbearing potential or male of any race, between 18 to 55 years of age (inclusive) at the time of signing the ICF, and in good health as determined by the screening history and Physical examination (PE).
  3. Agrees to abide by the requirements and restrictions outlined in the CC-92480 Pregnancy Prevention Plan for Participants in Clinical Trials.
  4. For males:

    a. Practice true abstinence (which must be reviewed on a monthly basis, as applicable) or agree to use a barrier not made of natural (animal) membrane (eg, latex or polyurethane condoms are acceptable) when engaging in sexual activity with a female of (FCBP) while on study medication, and for at 3 months after the last dose of study medication even if he has undergone a successful vasectomy.

  5. For females:

    Female participants must have been surgically sterilized (hysterectomy or bilateral oophorectomy; proper documentation required) at least 6 months before screening or be (defined as 24 months without menses before screening, with a serum follicle-stimulation hormone (FSH) level of > 40 IU/L at screening.

  6. Must have a between 18 and 33 kg/m2 (inclusive) at the time of signing the ICF.
  7. Clinical laboratory test results must be within the respective reference ranges; or if not, the results be clinically insignificant according to the Investigator's medical judgment.
  8. Participant must agree and be willing to consume a standard high-fat meal (which may contain gluten), for Part 2 participants only.

Exclusion criteria

Exclusion Criteria:

The presence of any of the following will exclude a participant from enrollment:

  1. Female of , pregnant, or breastfeeding.
  2. History of any and relevant neurological, gastrointestinal (GI), renal, hepatic, cardiovascular, psychological, pulmonary, metabolic, endocrine, hematological, allergic disease, drug allergies, or other major disorders as determined by the Investigator.
  3. History of severe (eg, anaphylactic, anaphylactoid, Stevens-Johnson, angioedematous) reaction to a drug, or adverse reactions to multiple drugs.
  4. Use of any prescribed systemic or topical medication (including but not limited to analgesics, anesthetics, etc) within 28 days of the first dose administration.
  5. Use of any nonprescribed systemic or topical medication (including vitamin/mineral supplements, and herbal medicines) within 14 days of the first dose administration.
  6. Donation of blood or plasma within 8 weeks before the first dose administration to a blood bank or blood donation center.
  7. History of drug abuse (as defined by the current version of the Diagnostic and Statistical Manual [DSM]) within 2 years before first dose administration, or positive drug screening test reflecting consumption of illicit drugs.
  8. History of alcohol abuse (as defined by the current version of the DSM) within 2 years before first dose administration, or positive alcohol screen.
  9. Known to have serum hepatitis or known to be a carrier of surface antigen (HBsAg) or antibody (HCV Ab), or have a reactive result to the test for (HIV) antibodies at screening.
  10. Use of tobacco- or nicotine-containing products within 3 months prior to Day -1, as assessed by medical history and physical examination, or positive urine cotinine test at screening.
  11. Vaccination within 30 days of first dose administration or plans to receive vaccination (live and attenuated) within 30 days after dosing.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    CC-92480-02 (Formulation A) with Placebo

    CC-92480-02 (Formulation A) or matching placebo to be administered orally under fasted conditions.

    Drug: CC-92480 · Other: Placebo

  • Experimental
    CC-92480 (Formulation B)- fasted condition

    A single oral dose of CC-92480 (Formulation B) administered under fasted conditions.

    Drug: CC-92480

  • Experimental
    CC-92480-02 (Formulation A) - fasted condition

    A single oral dose of CC-92480-02 (Formulation A) administered under fasted conditions.

    Drug: CC-92480

  • Experimental
    CC-92480 (Formulation B) - Low-fat meal

    A single oral dose of CC-92480 (Formulation B) administered under fed conditions (low-fat meal).

    Drug: CC-92480

  • Experimental
    CC-92480-02 (Formulation A) - high-fat meal

    A single oral dose of CC-92480-02 (Formulation A) administered under fed conditions (high-fat meal).

    Drug: CC-92480

Interventions

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics- Cmax Part 1

    Maximum plasma concentration of drug

    Time frame: Up to 96 hours after dosing

  2. Pharmacokinetics- Tmax Part 1

    Time to maximum plasma concentration

    Time frame: Up to 96 hours after dosing

  3. Pharmacokinetics- AUC0-∞Part 1

    Area under the plasma concentration-time curve from time zero to infinity

    Time frame: Up to 96 hours after dosing

  4. Pharmacokinetics- AUC0-t Part1

    Area under the plasma concentration-time curve from time zero to the last observable concentration

    Time frame: Up to 96 hours after dosing

  5. Pharmacokinetics- t½ Part 1

    Terminal elimination half-life

    Time frame: Up to 96 hours after dosing

  6. Pharmacokinetics- CL/F Part 1

    Apparent total plasma clearance

    Time frame: Up to 96 hours after dosing

  7. Pharmacokinetics- Vz/F Part 1

    Apparent volume of distribution

    Time frame: Up to 96 hours after dosing

  8. Pharmacokinetics- tlag Part 1

    Lag time between time of administration and start of absorption

    Time frame: Up to 96 hours after dosing

  9. Pharmacokinetics- Cmax Part 2

    Maximum plasma concentration of drug

    Time frame: Up to 96 hours after dosing

  10. Pharmacokinetics- Ratio of Cmax (Formulation A/Formulation B) Part 2

    Ratio of maximum plasma concentration of drug

    Time frame: Up to 96 hours after dosing

  11. Pharmacokinetics- AUC0-∞ Part 2

    Area under the plasma concentration-time curve from time zero to infinity

    Time frame: Up to 96 hours after dosing

  12. Pharmacokinetics- Ratio of AUC0-∞ (Formulation A/Formulation B) Part 2

    Ratio of area under the plasma concentration-time curve from time zero to infinity

    Time frame: Up to 96 hours after dosing

  13. Pharmacokinetics- AUC0-t Part 2

    Area under the plasma concentration-time curve from time zero to the last observable concentration

    Time frame: Up to 96 hours after dosing

  14. Pharmacokinetics- AUC0-t (Formulation A/Formulation B) Part 2

    Area under the plasma concentration-time curve from time zero to the last observable concentration

    Time frame: Up to 96 hours after dosing

  15. Pharmacokinetics- Tmax Part 2

    Time to maximum plasma concentration

    Time frame: Up to 96 hours after dosing

  16. Pharmacokinetics- t½ Part 2

    Terminal elimination half-life

    Time frame: Up to 96 hours after dosing

  17. Pharmacokinetics- CL/F Part 2

    Apparent total plasma clearance

    Time frame: Up to 96 hours after dosing

  18. Pharmacokinetics- Vz/F Part 2

    Apparent volume of distribution

    Time frame: Up to 96 hours after dosing

  19. Pharmacokinetics- tlag Part 2

    Lag time between time of administration and start of absorption

    Time frame: Up to 96 hours after dosing

Secondary outcomes

  1. Pharmacokinetics- Cmax (high-fat meal)

    Maximum plasma concentration of drug

    Time frame: Up to 96 hours after dosing

  2. Pharmacokinetics- Ratio (Fed/Fasted) of Cmax (high-fat meal)

    Ratio of maximum plasma concentration of drug

    Time frame: Up to 96 hours after dosing

  3. Pharmacokinetics- AUC0-∞(high-fat meal)

    Area under the plasma concentration-time curve from time zero to infinity

    Time frame: Up to 96 hours after dosing

  4. Pharmacokinetics- Ratio (Fed/Fasted) of AUC0-∞ (high-fat meal)

    Ratio of area under the plasma concentration-time curve from time zero to infinity

    Time frame: Up to 96 hours after dosing

  5. Pharmacokinetics- AUC0-t (high-fat meal)

    Area under the plasma concentration-time curve from time zero to the last observable concentration

    Time frame: Up to 96 hours after dosing

  6. Pharmacokinetics- Ratio (Fed/Fasted) of AUC0-t (high-fat meal)

    Ratio of area under the plasma concentration-time curve from time zero to the last observable concentration

    Time frame: Up to 96 hours after dosing

  7. Pharmacokinetics- Tmax (high-fat meal)

    Time to maximum plasma concentration

    Time frame: Up to 96 hours after dosing

  8. Pharmacokinetics- AUC0-24 (high-fat meal)

    Area under the plasma concentration-time curve from time zero to 24 hours post dose

    Time frame: Up to 96 hours after dosing

  9. Pharmacokinetics- t½ (high-fat meal)

    Terminal elimination half-life

    Time frame: Up to 96 hours after dosing

  10. Pharmacokinetics- CL/F (high-fat meal)

    Apparent total plasma clearance

    Time frame: Up to 96 hours after dosing

  11. Pharmacokinetics- Vz/F (high-fat meal)

    Apparent volume of distribution

    Time frame: Up to 96 hours after dosing

  12. Pharmacokinetics- tlag (high-fat meal)

    Lag time between time of administration and start of absorption

    Time frame: Up to 96 hours after dosing

  13. Pharmacokinetics- Cmax (low-fat meal)

    Maximum plasma concentration of drug

    Time frame: Up to 96 hours after dosing

  14. Pharmacokinetics- Ratio (Fed/Fasted) of Cmax (low-fat meal)

    Ratio of maximum plasma concentration of drug

    Time frame: Up to 96 hours after dosing

  15. Pharmacokinetics- AUC0-∞(low-fat meal)

    Area under the plasma concentration-time curve from time zero to infinity

    Time frame: Up to 96 hours after dosing

  16. Pharmacokinetics- Ratio (Fed/Fasted) of AUC0-∞(low-fat meal)

    Ratio of area under the plasma concentration-time curve from time zero to infinity

    Time frame: Up to 96 hours after dosing

  17. Pharmacokinetics- AUC0-t (low-fat meal)

    Area under the plasma concentration-time curve from time zero to the last observable concentration

    Time frame: Up to 96 hours after dosing

  18. Pharmacokinetics- Ratio (Fed/Fasted) of AUC0-t (low-fat meal)

    Ratio of area under the plasma concentration-time curve from time zero to the last observable concentration

    Time frame: Up to 96 hours after dosing

  19. Pharmacokinetics- Tmax (low-fat meal)

    Time to maximum plasma concentration

    Time frame: Up to 96 hours after dosing

  20. Pharmacokinetics- t½ (low-fat meal)

    Terminal elimination half-life

    Time frame: Up to 96 hours after dosing

  21. Pharmacokinetics- CL/F (low-fat meal)

    Apparent total plasma clearance

    Time frame: Up to 96 hours after dosing

  22. Pharmacokinetics- Vz/F (low-fat meal)

    Apparent volume of distribution

    Time frame: Up to 96 hours after dosing

  23. Pharmacokinetics- tlag (low-fat meal)

    Lag time between time of administration and start of absorption

    Time frame: Up to 96 hours after dosing

  24. Incidence of Adverse Events (AEs)

    An AE is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a participant during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the participant's health, including laboratory test values, regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE.

    Time frame: From enrollment until at least 28 days after completion of study treatment

07

Study locations

1 site
  • PPD Phase 1 Clinic
    Austin, Texas 78744, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2021 to primary completion in Oct 2021, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2021
First posted
Apr 9, 2021
StartActual
Jan 19, 2021
Primary completionActual
Oct 8, 2021
CompletionActual
Oct 8, 2021
Last update
Dec 10, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 10, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT04839809
Lead sponsor
Celgene
Responsible party
Sponsor
First posted
Apr 9, 2021
Start date
Jan 19, 2021
Primary completion
Oct 8, 2021
Completion
Oct 8, 2021
Last update
Dec 10, 2021

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Mezigdomide

Start the discussion